drugset / Trial / NCT05495295
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
NaSingle-groupOpen-labelTreatment
Summary
The PhAST Trial is an adaptive first-in-human clinical trial of the acetylglucosaminyltransferase V inhibitor PhOx430 in patients with advanced solid tumours conceived and designed with the contribution of the Gianni Bonadonna Foundation, a non-profit academic research institution aimed at promoting therapeutic innovation in oncology.. The trial includes two parts, a dose escalation phase which will enroll patients with non-selected tumour types, followed by a cohort expansion phase in selected tumour types.
Timeline
- Start
- 2022-07-18
- Primary completion
- 2024-11-04
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PhOx430 | Unknown | 10 mg/kg | Oral |
| Subject | PhOx430 | Unknown | 20 mg/kg | Oral |
| Subject | PhOx430 | Unknown | 40 mg/kg | Oral |
| Subject | PhOx430 | Unknown | 70 mg/kg | Oral |
| Subject | PhOx430 | Unknown | 600 mg | Oral |
| Subject | PhOx430 | Unknown | 1200 mg | Oral |